Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:33:57.893Z.
Calculation as of: 2026-10-06T17:33:57.893Z.
Quote observation: 2026-10-06T17:30:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$64.37M
Price/OCF Ratio
N/A
TTM Avg
1.86
3Y Avg
1.86
5Y Avg
1.86
Market Cap
$63.16M
Price/OCF Ratio
N/A
TTM Avg
44.68
3Y Avg
44.68
5Y Avg
44.68
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RenovoRx, Inc. (RNXT) | $63.97M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.37M | N/A | 1.86 | 1.86 | 1.86 |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.99M | N/A | 35.67 | 35.67 | 35.67 |
| Cingulate Inc. (CING)vs › | $66.20M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | N/A | 44.68 | 44.68 | 44.68 |
| InterCure Ltd. (INCR)vs › | $65.15M | 6.91 | 5.29 | 5.29 | 30.61 |
| XBiotech Inc. (XBIT)vs › | $66.46M | N/A | 4.25 | 4.25 | 4.25 |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.17M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $67.38M | N/A | 15.38 | 92.53 | 55.53 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
